alpha-2-adrenoceptor Inhibitors
1 drugsAbout alpha-2-adrenoceptor
The alpha-2-adrenoceptor family are G protein-coupled receptors activated by catecholamines like norepinephrine and epinephrine. They regulate neurotransmitter release, blood pressure, and insulin secretion. As such, they have long been a target of pharmaceutical intervention.
Currently, there is no genetic evidence data available linking alpha-2-adrenoceptors to specific diseases. However, the existing pharmacological evidence underscores its importance as a drug target.
There is one FDA-approved drug, DURACLON (clonidine), targeting this receptor. DURACLON, marketed by Viatris, is a small molecule approved in 1996 with applications in oncology.
Top alpha-2-adrenoceptor Drugs
Viatris is the only company with an approved drug targeting alpha-2-adrenoceptors.
Low competition suggests a potential market opportunity, but also a higher risk due to lack of validation by multiple players.
alpha-2-adrenoceptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha-2-adrenoceptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics or drug delivery systems.
alpha-2-adrenoceptor Clinical Trials 70 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha-2-adrenoceptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 7 | 1 | 1 | 88% |
| Phase 2 | 22 | 13 | 6 | 2 | 68% |
| Phase 3 | 12 | 10 | 2 | 0 | 83% |
| Phase 4 | 27 | 17 | 6 | 4 | 74% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha-2-adrenoceptor Drug Approval Timeline (1996 - 1996)
The first and only drug, DURACLON, was approved in 1996.
The lack of recent approvals indicates potential saturation or challenges in developing new alpha-2-adrenoceptor modulators.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 59 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha-2-adrenoceptor. A trial counts if an approved drug acting on alpha-2-adrenoceptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.